Innovation at the Interface between Academia and Industry: The BioMed X Model

In the evolving landscape of biomedical research, the convergence of molecular biology and translational medicine has ushered in a new era of pharmaceutical innovation. This paradigm shift, characterized by significant advances in targeted therapies and gene editing, emphasizes the critical role of integrating academic research - and academic researchers - within industry settings. Contemporary innovation models are moving beyond traditional, corporation-centered frameworks, adopting more open, collaborative approaches. Here, we discuss the challenges and solutions brought about by this new direction in pharma innovation and describe the BioMed X innovation model, a unique open innovation approach that has been growing continuously over the past ten years.